RLAY
Relay Therapeutics, Inc.Company with tickers: RLAY
CIK
1812364
CUSIP
75943R102
Shares Outstanding
214,502,832
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | $3,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Revenue (ASC 606) | $3,000,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $81,590,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | — | ||||
| Operating Income | $-78,590,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-73,291,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $-0.41 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-0.41 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |